Psychedelic Therapy in Ireland: Every Legal Route in 2026

If you are considering psychedelic-assisted treatment in Ireland — for yourself or for someone close to you — the honest map in July 2026 has one publicly funded route, a private market that barely exists yet, and a research scene that is stronger than the country's size suggests. This guide covers who qualifies for each real route, how to start, what it costs, and what to realistically expect; you can begin orienting yourself with our eligibility check.

At a glance

Esketamine (Spravato): reimbursed, psychiatrist-initiated, few doors

Ireland approved reimbursement of esketamine nasal spray in January 2022, following confidential price negotiations between the HSE and the manufacturer after the national health-technology assessment (NCPE HTA ID 19055). The reimbursed indication is treatment-resistant major depressive disorder in adults — a moderate-to-severe episode that has not responded to adequate trials of antidepressants — used in combination with an SSRI or SNRI, per the EU label (EMA product information).

Two features define the Irish route in practice:

• The decision to prescribe sits with a psychiatrist. Your GP cannot start esketamine; their role is to refer you into psychiatric care with a documented treatment history. Once prescribed, you self-administer the spray under the direct supervision of a healthcare professional, followed by an observation period.
• Delivery is concentrated, not universal. Reimbursement is a funding decision, not a capacity decision. Uptake has been limited and clustered in specialist psychiatric services, because supervised administration demands space, staff and a monitoring routine (Blossom: Ireland country report). Expect your psychiatrist to know whether a programme runs in your catchment area — and expect the honest answer in some regions to be "not yet". Galway has been a visible growth point, with HSE material showing esketamine services presented for treatment-resistant depression in the west.

How to start. Bring your psychiatrist — or ask your GP for a referral into secondary care — a written treatment history: every antidepressant tried in the current episode, with substance, dose, duration and outcome, plus any augmentation and psychotherapy. That record is what turns "we could consider esketamine" into a scheduled assessment. For patients who qualify through public services, treatment is covered; for how Ireland compares with its neighbours, see our Europe-wide reimbursement map.

Private ketamine-assisted psychotherapy: announced, not yet open

Ireland does not have the private ketamine-clinic market of the UK or Germany. As of July 2026, the visible private development is Neuromed Clinic Ireland (neuromedclinicireland.ie) — a medically led mental-health provider with clinics in Dublin (Ranelagh) and Galway, currently offering transcranial magnetic stimulation (TMS), MeRT and mental-health assessments — which has announced a ketamine-assisted psychotherapy programme launching in autumn 2026. No prices are published, and the programme's screening criteria are not yet public.

What this means practically: if you are researching Irish KAP today, you are researching a waiting room, not a treatment. Reasonable steps are to register interest with the clinic, ask what the programme will include (medical screening, preparation, supervised administration, integration), what it will cost in writing, and which physicians will run the medical side. Treat any Irish offer of ketamine therapy that is available immediately, without psychiatric screening, with caution — and check what is listed near you by browsing providers in Ireland.

Psilocybin: research only — with a real Irish research scene

Psilocybin and psilocin are Schedule 1 controlled substances in Ireland, and psilocin-containing mushrooms have been expressly controlled since 2006; lawful use is confined to licensed research (Blossom: Ireland country report). No compassionate-access or special-access route exists. The research scene, however, is one of the more credible in Europe for a country of five million:

• The live opportunity in July 2026 is the Phase 3 CYB003 (EMBRACE) trial — a deuterated psilocin analog studied as an adjunct in major depressive disorder — recruiting at Sheaf House, Tallaght Adult Mental Health Service in Dublin and La Nua Day Hospital Mental Health Centre in Galway (NCT06793397).
• The track record runs through the Trinity College Dublin and Tallaght University Hospital Psychedelic Research Group: Tallaght was an Irish site in the COMP360 psilocybin Phase 2b trial in treatment-resistant depression, published in the New England Journal of Medicine in 2022, and Ireland participates in the follow-on Phase 3 COMP360 programme (active, no longer enrolling).
• The pipeline is broadening: Trinity lists projects including POSITRON, a pilot psilocybin feasibility study for cocaine use disorder, and Dublin-headquartered GH Research published Phase 2b results for its 5-MeO-DMT compound GH001 (mebufotenin) in treatment-resistant depression in 2026.

If your situation fits the CYB003 trial's profile — adults with major depressive disorder — ask your psychiatrist or GP about a referral to the Tallaght or Galway study team. Outside a trial, anyone selling psilocybin therapy in Ireland today is committing an offence.

MDMA: no route, not even a trial

MDMA is a Schedule 1 controlled substance in Ireland with no medical-access route — and unlike psilocybin, there is no Irish research foothold either. As of July 2026, no MDMA trial with an Irish site is recruiting or has been registered: a ClinicalTrials.gov search for MDMA studies in Ireland returns none, and Blossom's Ireland tracker lists no MDMA study among the country's thirteen linked trials. If MDMA-assisted therapy matters to you, the realistic options are watching the registries or considering trial sites elsewhere in Europe — our trials guide explains how to search and what participation involves. Anyone offering MDMA therapy commercially in Ireland today is operating illegally.

Clinical trials in Ireland

Blossom currently tracks 13 psychedelic clinical trials connected to Ireland, 2 of them active, with ketamine and psilocybin the most-studied compounds and depression the dominant topic (Blossom: Ireland country report). Beyond the psilocybin work above, Irish ketamine research is mature enough to produce negative findings worth knowing: the St Patrick's-linked KARMA-Dep 2 trial reported in October 2025 that serial ketamine infusions added no benefit in hospitalised depression — a result that should temper expectations about ketamine as a cure-all. Dublin and Tallaght form the main hub, with Galway now a genuine second node. Participation is free and legal, but screening is strict and enrolment is never guaranteed, and trial screening can run in parallel with a public esketamine referral. See the trials guide for how phases, placebo and consent work, and search ClinicalTrials.gov for current Irish listings.

What to expect in treatment

Whichever route you take, the shape of care is similar and worth picturing in advance. It begins with a screening appointment: the clinician reviews your psychiatric and medication history, checks your cardiovascular health and current medicines, and confirms the diagnosis before anything is scheduled. This is also where contraindications are caught.

On a Spravato day you attend the psychiatric service and self-administer the nasal spray under supervision, then stay for an observation period of roughly two hours while staff monitor blood pressure, heart rate and how you feel; a detached, dreamlike sensation and a temporary rise in blood pressure are expected effects that settle as the drug clears. You must not drive for the rest of the day, so arrange a lift home. Induction sessions are typically twice weekly at first and then taper based on measured response, alongside a continuing oral antidepressant.

In a trial, add a research layer: longer screening, structured rating scales, possible randomisation to a comparator, and scheduled follow-up visits — plus, in psilocybin-type studies, supervised dosing sessions that last most of a day with preparation and integration appointments around them. In every setting the medicine is one part of the plan: screening, monitoring and follow-up are what make it safe, and psychotherapy or integration is what helps the effect last.

Risks and who should not start

These treatments are generally well tolerated under supervision, but they are not for everyone, which is exactly what screening is for. Common, transient effects during or shortly after a session include dissociation, nausea, mild perceptual changes and a short-lived rise in blood pressure and heart rate; these resolve as the drug is metabolised. Treatment may be inappropriate, or require particular caution and specialist evaluation, when any of the following apply:

• Uncontrolled hypertension or significant cardiovascular instability, including a history of aneurysmal vascular disease, because of the temporary rise in blood pressure.
• A personal or family history of psychosis or bipolar disorder — a particular caution for classic psychedelics such as psilocybin and its analogs, which Irish trial protocols screen for carefully.
• Severe liver disease or other serious somatic illness.
• Pregnancy or breastfeeding.
• Substance-use concerns, particularly patterns of compulsive use; services also screen for acute suicidality risk before outpatient treatment.

A responsible provider screens for all of these before the first session. If any service is willing to treat you without that assessment, treat it as a warning sign.

Frequently asked questions

Is Spravato free in Ireland?

For patients who qualify through public specialist psychiatric services, yes — the HSE has reimbursed it since January 2022. The gatekeepers are clinical: a psychiatrist must initiate treatment, and a supervised-administration site must have capacity in your area.

Can my GP prescribe esketamine or refer me directly to a session?

No. The decision to prescribe sits with a psychiatrist. Your GP's role — and it is an important one — is to refer you into psychiatric care with a documented treatment history that makes the assessment fast.

Is there anywhere in Ireland I can book ketamine-assisted psychotherapy today?

Not as of July 2026. Neuromed Clinic (Dublin and Galway) has announced a KAP programme launching in autumn 2026, without published prices. Some Irish patients have historically looked at services in Northern Ireland or Great Britain; if you do, apply the same screening-and-written-costs checklist.

How do I join the Irish psilocybin-analog trial?

The Phase 3 CYB003 (EMBRACE) trial for major depressive disorder is recruiting at Tallaght Adult Mental Health Service (Sheaf House) in Dublin and La Nua Day Hospital in Galway. Ask your psychiatrist or GP about a referral to the study team, and read the entry criteria on the registry first (NCT06793397).

Can I get MDMA therapy in Ireland?

No — not in care, and currently not even in research. No Irish MDMA trial exists as of July 2026. Watch the registries or consider trial sites elsewhere in Europe.

How long will I wait for each route?

Public esketamine: the psychiatric referral plus whether a programme runs in your region — weeks to months, and honest regional gaps exist. Private KAP: at least until autumn 2026. Trials: screening typically takes weeks, with no guarantee of enrolment, and can run in parallel with a public referral.

Sources

1. NCPE — Esketamine (Spravato) HTA ID 19055
2. Irish Medical Times: Spravato approved for reimbursement in Ireland for adults with treatment-resistant major depressive disorder (2022)
3. Blossom: Ireland country report
4. Blossom: Medical access in Ireland
5. Psychedelic Alpha: Worldwide psychedelic laws tracker
6. EMA: Spravato (esketamine) EPAR
7. ClinicalTrials.gov: NCT06793397 — CYB003 (EMBRACE) Phase 3 in major depressive disorder (recruiting; Dublin and Galway sites)
8. Trinity College Dublin — Psychedelic Research Group (Trinity and Tallaght)
9. Trinity College Dublin: Promising results from psilocybin therapy trial for treatment-resistant depression (COMP360 Phase 2b, Tallaght site)
10. NEJM: Single-dose psilocybin for a treatment-resistant episode of major depression (COMP360 Phase 2b)
11. PubMed: KARMA-Dep 2 — adjunctive serial ketamine in hospitalised depression (2025)
12. Neuromed Clinic Ireland — services and KAP programme announcement

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations and reimbursement rules change; always verify current requirements with the HSE, your psychiatrist, or a licensed clinician who knows your history. If you are in crisis, contact emergency services (112 or 999) or the Samaritans on 116 123 immediately.

This guide awaits review by a licensed medical professional.